According to Research by SNS Insider, the growth of the liquid biopsy market is driven by significant technological advancements and a growing preference for minimally invasive procedures.Pune, March ...

Updated results of an Australian trial which used liquid biopsies to guide colon cancer treatment has confirmed no compromise ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

With an at least $60 billion total addressable market, the liquid biopsy sector offers abundant opportunity for multiple companies to swim to the top. The six largest companies in the pool have just ...

This could potentially be used as a standalone pan-cancer test or, given its low false positive rate among healthy people, be licensed out for use in conjunction with other liquid biopsy ...

VolitionRx (VNRX) announces the results of a study which shows that an automated Nu.Q Cancer immunoassay test in development detected a range ...

Every year, 1.8 million people lose their lives to lung cancer, making it one of the deadliest diseases and one of the leading causes of cancer-related deaths worldwide. A major reason for the high ...

Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further ...